QDEL · QuidelOrtho Corporation

QuidelOrtho’s preliminary Q1 2026 results reflect material near-term headwinds across key geographies and product lines. Revenue of $615–$620 million — centered at $617.5 million — fell short of typical seasonal expectations, primarily due to a significantly weaker U.S. respiratory season, with CDC-reported influenza-like illness visits down approximately 30% year-over-year. This directly impaired demand for the Company’s rapid respiratory assays, which constitute a substantial portion of its near-term revenue. Additionally, distributor sales in China slowed amid anticipated reimbursement rate reductions by the National Health Security Administration (NHSA), signaling potential pricing pressure and channel inventory caution ahead of policy implementation. Operational execution was further disrupted in EMEA, where orders were delayed due to the ongoing Middle East conflict — a supply chain and logistics constraint explicitly cited as revenue-negative. Management emphasized that its core business — representing over 70% of total revenue — remains resilient, underscoring underlying franchise strength despite volatility. The Company confirmed it is taking decisive cost actions to offset near-term softness and maintain full-year 2026 profitability and positive free cash flow, though Q1 free cash flow is expected to be meaningfully negative at $(65)–$(70) million. While full-year guidance remains intact at the low end, the broad original range reflects deliberate conservatism around respiratory season variability and unresolved macro risks — including China NHSA policy outcomes and geopolitical instability. Investors should monitor the May 5, 2026 earnings release and call for confirmation of these dynamics and any refinement to guidance or margin outlook.